In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Biotronik SE & Co. KG

www.biotronik.com

Latest From Biotronik SE & Co. KG

Biotronik Starts First ICD Study Designed To Measure Sex-Specific Outcomes

BIO-LIBRA will study Biotronik ICDs and CRT-D devices in about 1,000 patients with non-ischemic cardiomyopathy. The investigators expect at least 40% of the subjects in BIO-LIBRA to be women.

Clinical Trials Research & Development

Biotronik Begins US Rollout Of PK Papyrus For Coronary Perforations

The US FDA granted PK Papyrus a humanitarian device exemption (HDE) in late 2018, the first FDA approval of a device to treat coronary perforations since Abbott's Jomed Jostent earned an HDE in 2001.

Approvals Innovation

Boston Scientific’s Synergy Stent Narrowly Outperforms Biosensors’ Biomatrix NeoFlex In Danish Study

Data from the 2,770-patient randomized SORT OUT VIII trial showed Boston Scientific’s Synergy everolimus-eluting stent is noninferior to Biosensor’s Biomatrix NeoFlex Biolimus-eluting stent for the endpoint of target lesion failure, but the procedure failure-rate was lower in the Synergy patients, which may have led to lower overall rates of myocardial infarction.

Clinical Trials Commercial

Results Recap: CRT In DC Features New Biotronik Stent Data, Encouraging TAVR Low-Risk Data; Ablative Systems’ Alcohol Renal Denervation

Medtech Insight's Results Recap covers major device trial results appearing on MedDeviceTracker. This week's edition, covering March 1 to March 7, includes results of late-breaking trials presented at the 2019 Cardiovascular Research Technologies (CRT) conference in Washington, DC, including new data supporting Biotronik’s biodegradable polymer sirolimus-eluting stent and the company’s resorbable magnesium stent, results of the LRT trial of transcatheter aortic valves in low-risk patients, plus promising clinical data supporting Ablative System’s alcohol renal-denervation system.

Tracking Trials Clinical Trials
See All

Company Information

  • Industry
  • Medical Devices
    • Implantable Devices
    • Surgical Equipment & Devices
      • Minimally or Less Invasive
  • Therapeutic Areas
  • Cardiovascular
  • Alias(es)
  • Biotronik GMBH & Co.
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • Europe
      • Western Europe
        • Germany
  • Parent & Subsidiaries
  • Biotronik SE & Co. KG
  • Senior Management
  • Marlou Janssen, Global VP, Mktg. & Sales
  • Contact Info
  • Biotronik SE & Co. KG
    Phone: (49) 30 6 89 050
    Woermannkehre 1
    Berlin, D-12359
    Germany
Advertisement
Advertisement
UsernamePublicRestriction

Register